The Opioid Epidemic and Infectious Diseases
- 1st Edition - November 15, 2019
- Imprint: Elsevier
- Editor: Brianna L. Norton
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 6 8 3 2 8 - 9
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 6 8 3 2 9 - 6
Offering timely guidance on the junction of the opioid crisis and infectious diseases, this practical handbook by Dr. Brianna L. Norton provides concise yet comprehensive co… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteOffering timely guidance on the junction of the opioid crisis and infectious diseases, this practical handbook by Dr. Brianna L. Norton provides concise yet comprehensive coverage of a growing patient population. Infectious disease specialists are increasingly seeing patients who previously used opiods and now use intravenous drugs. Many challenges are unique to this patient population, including new and growing infections such as hepatitis C, endocarditis, HIV, and hepatitis B. The Opioid Epidemic and Infectious Diseases is an up-to-date, real-world guide that covers the scope of the problem, management guidelines, and much more.
- Describes the new landscape of the opioid crisis in the U.S. and its intersection with infectious diseases, including epidemiology, Opioid Use Disorder (OUD) and rural America, and more.
- Offers practical guidance on (OUD) and infectious co-morbidities like hepatitis C, STDs, endocarditis, HIV, and hepatitis B.
- Covers prevention, treatment, and harm reduction.
- Discusses OUD, infectious diseases, and the criminal justice system.
- Consolidates today’s available information and guidance into a single, convenient resource.
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Chapter 1. The epidemiology of the opioid overdose epidemic in the United States
- Introduction
- National trends and demographics
- The triple-wave epidemic: opioid pills, heroin, and synthetic opioids
- Conclusion
- Chapter 2. The case of Scott County: injection drug use and the HIV and hepatitis C virus outbreak
- Background
- Outbreak
- Burden of injection drug use throughout the United States and the world, and association of injection drug use with HIV and hepatitis C virus infections
- Acute hepatitis C virus infection and injection drug use in areas at risk for HIV outbreaks
- Management of HIV outbreaks, methods for amelioration of existing outbreaks, and prevention of future outbreaks
- Other recent outbreaks
- Scott County may be the harbinger of things to come
- Chapter 3. Opioid use disorder and rural America
- Opioid use disorder burden in rural communities
- Human immunodeficiency virus
- Hepatitis C, B, and A virus infections
- Factors that drive illicit drug use in rural communities
- Barriers to care in rural communities
- Developing and training the rural healthcare workforce
- Community stigma, support, and policy
- Promising models for prevention and treatment in rural communities
- Current studies on rural injection drug use
- Chapter 4. Opioid use disorder, infectious diseases, and the criminal justice system
- Background on criminal justice in the United States
- Bloodborne illnesses in criminal justice settings
- Medications for addiction (opioid use disorder) treatment
- Chapter 5. Opioid use disorder and HIV
- Injection drug use is an important HIV risk factor
- Factors contributing to declining HIV incidence among PWID: 1992–2015
- The current opioid epidemic threatens decades of decline in PWID-related HIV
- Treatment of HIV-positive people with opioid use disorder or who inject drugs
- Conclusion
- Chapter 6. Opioid use disorder and HCV (hepatitis C virus)
- Introduction
- Epidemiology
- Natural history of HCV and mortality
- Screening of HCV among PWID and point-of-care testing
- Staging of liver disease and HCC screening
- SVR outcomes in PWID
- Barriers to care for PWID
- Cascade of care and Co-located models of care
- HCV treatment adherence
- HCV reinfection
- Treatment as prevention
- Policy issues and restrictions
- Cost-effectiveness studies
- Conclusions
- Chapter 7. Opioid use disorder and Chronic Hepatitis B
- Introduction
- Natural history of hepatitis B virus infection
- Hepatitis B virus infection epidemiology, with focus on persons who inject drugs
- Hepatitis B and other coinfections in persons who inject drugs
- Hepatitis B virus screening and diagnosis
- Prevention: Hepatitis B virus vaccination
- Treatment of hepatitis B
- Chapter 8. Opioid use disorder and endocarditis
- Opioid use disorder and endocarditis
- IDU-associated endocarditis: diagnosis and treatment
- Other treatment issues
- Addiction treatment for hospitalized patients: an opportunity to intervene
- Chapter 9. Outpatient opioid use disorder treatment for the ID physician
- Benefits of opioid use disorder treatment
- To treat opioid use disorder successfully, recognize that it is a chronic, relapsing and remitting disease of the brain
- Barriers to opioid use disorder treatment
- Scale-up of opioid use disorder treatment is a critical public health priority: an overview of expansion strategies
- Expansion of opioid use disorder pharmacologic treatment in nonaddiction specialty clinics is a promising public health strategy
- Legislative history for expanding access to pharmacotherapy in the ambulatory setting
- Clinician-level barriers to prescribing treatment for opioid use disorder
- Screening for opioid use disorder, the benefit of treatment initiation, and additional work up
- Available pharmacotherapy options for treating opioid use disorder
- Special considerations in opioid use disorder pharmacologic treatment
- Conclusion
- Chapter 10. Inpatient opioid use disorder treatment for the infectious disease physician
- Introduction
- Pathophysiology of infections related to OUD
- Inpatient OUD screening in the infectious disease consultation
- Withdrawal treatment with transition to medication maintenance
- Medications for OUD
- Inpatient infections
- Patient-centered care
- Acute pain
- Opioid-related medical conditions
- Future directions
- Chapter 11. HIV pre-exposure prophylaxis for people who inject drugs
- HIV prevention in people who inject drugs
- Evidence of efficacy of preexposure prophylaxis in people who inject drugs
- Preexposure prophylaxis effectiveness in the “real world”
- Indications for preexposure prophylaxis in people who inject drugs
- The HIV prevention or preexposure prophylaxis care continuum
- Challenges facing scale-up and widespread adoption
- Strategies for preexposure prophylaxis scale-up among people who inject drugs
- Advances in preexposure prophylaxis modalities and the future of preexposure prophylaxis for people who inject drugs
- Chapter 12. Notes on harm reduction and the opioid epidemic in the United States
- Introduction
- What harm reduction is not
- Positive principles of harm reduction
- Historical timeline of harm reducing and harm-increasing events in the United States
- Harm reduction and the current opioid epidemic
- Tips for clinicians
- Chapter 13. Modeling the impact of harm reduction for opioid use disorder on infectious disease prevention
- Introduction
- Empirical evidence for harm reduction on acquiring HIV and hepatitis C virus infections
- Modeling the impact of harm reduction on HIV epidemics among people who inject drugs in the United States
- Modeling hepatitis C virus infection and harm reduction in the United States
- Modeling the impact of harm reduction among the incarcerated population on infectious diseases
- Cost-effectiveness of harm reduction interventions in the United States
- Conclusion
- Index
- Edition: 1
- Published: November 15, 2019
- Imprint: Elsevier
- No. of pages: 300
- Language: English
- Paperback ISBN: 9780323683289
- eBook ISBN: 9780323683296
Read The Opioid Epidemic and Infectious Diseases on ScienceDirect